A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast
Status:
Recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
This is a open-labeled, single-arm, Investigator-initiated clinical trial of camrelizumab (an
anti-PD-1 antibody) in combination with radiotherapy in patients with early triple-negative
breast cancer. We will enroll 60 subjects. This study aims to evaluate the efficacy and
safety of camrelizumab combined with radiotherapy in the treatment of early TNBC。